RJA
IMUX icon

Raymond James & Associates’s Immunic IMUX Stock Holding History

Raymond James & Associates’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-33
Closed -$4K – 3624
2018
Q3 		$4K Sell
33
-2
-6% -$5.22K ﹤0.01% 3607
2018
Q2 		$96K Sell
35
-57
-62% -$132K ﹤0.01% 3406
2018
Q1 		$249K Buy
92
+24
+35% +$55.1K ﹤0.01% 3006
2017
Q4 		$161K Sell
68
-49
-42% -$108K ﹤0.01% 3123
2017
Q3 		$236K Sell
117
-44
-27% -$57.4K ﹤0.01% 2941
2017
Q2 		$186K Buy
161
+60
+59% +$80.1K ﹤0.01% 3006
2017
Q1 		$161K Buy
101
+70
+226% +$128K ﹤0.01% 2982
2016
Q4 		$53K Sell
31
-6
-16% -$13.1K ﹤0.01% 3093
2016
Q3 		$90K Hold
37
– – ﹤0.01% 3015
2016
Q2 		$92K Sell
37
-1
-3% -$3.29K ﹤0.01% 2817
2016
Q1 		$136K Buy
+38
New +$132K ﹤0.01% 2666
2015
Q3 		– Sell
-40
Closed -$335K – 2333
2015
Q2 		$335K Buy
40
+3
+8% +$28.6K ﹤0.01% 2246
2015
Q1 		$366K Buy
+37
New +$340K ﹤0.01% 2150

Other funds holding IMUX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Raymond James & Associates's IMUX Position: Q4 2018 in Review

Raymond James & Associates sold out of Immunic (IMUX) in Q4 2018, closing a stake of 33 shares — an estimated $4K sold.

Raymond James & Associates first reported a position in IMUX in Q1 2015 and held it in 13 quarters. The position peaked at $366K in Q1 2015. 47 funds tracked by Wall St. Rank hold IMUX as of Q4 2018.

  • Raymond James & Associates reported no remaining Immunic position as of Q4 2018 after selling out during the quarter.
  • Raymond James & Associates sold 33 Immunic shares in Q4 2018, an estimated $4K.
  • Raymond James & Associates first reported a position in Immunic in Q1 2015 and held it in 13 quarters.
  • Raymond James & Associates's Immunic position peaked at $366K in Q1 2015.
  • 47 funds tracked by Wall St. Rank held Immunic as of Q4 2018.

Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.